Keros Therapeutics
KROS
123 hedge funds and large institutions have $901M invested in Keros Therapeutics in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 60 increasing their positions, 27 reducing their positions, and 20 closing their positions.
2,490% more call options, than puts
Call options by funds: $518K | Put options by funds: $20K
122% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 27
4% less capital invested
Capital invested by funds: $937M → $901M (-$36M)
1.29% less ownership
Funds ownership: 77.1% → 75.81% (-1.3%)
5% less funds holding
Funds holding: 129 → 123 (-6)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Top Buyers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$50.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.31M |
| 4 |
CA
CHI Advisors
New York
|
+$6.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.95M |
Top Sellers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$39.7M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.8M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.77M |
| 4 |
Citigroup
New York
|
-$7.59M |
| 5 |
O
OrbiMed
New York
|
-$7.22M |
KROS Hedge Fund Activity: Q2 2023 in Review
123 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2023, worth a combined $901M — down 3.8% from $937M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KROS and 14 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 60 added.
The largest buyer was Braidwell, opening a new position worth an estimated $50.1M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $39.7M sold.
- 123 institutional investors held Keros Therapeutics (KROS) as of Q2 2023, down from 129 in Q1 2023.
- Funds reported $901M of Keros Therapeutics stock for Q2 2023, down 3.8% quarter-over-quarter.
- 14 funds opened new Keros Therapeutics positions in Q2 2023 and 20 closed out, a net change of -6 holders.
- The largest Keros Therapeutics buyer in Q2 2023 was Braidwell, an estimated $50.1M added.
- The largest Keros Therapeutics seller in Q2 2023 was Paradigm Biocapital Advisors, an estimated $39.7M sold.
Based on aggregated 13F filings for Q2 2023.